France's Neovacs takes on GSK and AstraZeneca in battle to treat lupus

PARIS, Sept 15 (Reuters) - French biotech company Neovacs is confident that its experimental drug to treat lupus could grab significant market share from standard treatments of the auto-immune disease, its chief executive said.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.